Immunicom, Inc., a clinical-stage biotechnology company pioneering “subtractive” advanced cancer therapies, presented promising preliminary data from trials investigating ImmunopheresisTM therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
The team at Edmonton-based KOVR tested the beta version of its new VR software platform, Stratos, and its first piece of education software, the Diabetic Retinopathy Module (DRM), this past month to a select group of patients.
This solution renders the virus non-infectious, enhancing the safety, sustainability and scalability of the testing process.
Glauconix Biosciences, Inc., leading developer of human 3D ocular tissues, and Nicox SA co-authored, a manuscript in Investigative Ophthalmology and Visual Sciences, demonstrating the IOP lowering ability of NCX 667, a novel nitric oxide donor.
It's estimated by the American Psychiatric Association that one in 11 people will be diagnosed with posttraumatic stress disorder (PTSD) in their lifetime, but new virtual reality (VR) technology is providing hope for the recovery of those suffering.
In the 40-some years since the beginning of the HIV/AIDS epidemic, scientists have learned a lot about the virus, the disease, and ways to treat it. But one thing they still don't completely understand is which exact cells are most susceptible to HIV infection.
New research published in BMJ Open outlines findings from a study on multiorgan impairment in individuals with persistent symptoms following recovery from COVID-19 infection— a condition referred to as long COVID. The study included characterization of organ function using global medical technology company Perspectum’s non-invasive imaging technology.
-Children’s Hospital Los Angeles (CHLA) is inviting supporters to participate in its inaugural Thank a Caregiver initiative in honor of National Nurses Week, May 6-12, and National Hospital Week, May 9-15.
In their effort to understand the very earliest stages of life and how they can go wrong, scientists are confronted with ethical issues surrounding the use of human embryos. The use of animal embryos is also subject to restrictions rooted in ethical considerations. To overcome these limitations, scientists have been trying to recreate early embryos using stem cells.
Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor, The Craftory, alongside TechBio investor ARTIS Ventures and life science investor GISEV, with participation from existing investors, Founders Fund and 8VC.